Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2V617F‐Positive Myeloproliferative Neoplasms

Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2V617F‐Positive Myeloproliferative Neoplasms

ABSTRACT Background The incidence, outcomes and risk factors for AF in the JAK2V617F‐positive MPN patients are still unknown. Methods The clinical profiles of patients with JAK2V617F‐positive MPN were retrospectively analyzed. Multivariable Cox regression analysis was performed to identify risk fact...

Full description

Saved in:

Bibliographic Details
Main Authors:	Guangshuai Teng, Ke Shang, Yuhui Zhang, Yifan Duan, Chenxiao Du, Yan Wang, Yanqi Li, Huiqin Zhang, Lan Peng, Xiaojing Wei, Gary Tse, Yuan Zhou, Gregory Y. H. Lip, Tong Liu, Wei Yang, Minghui Duan, Jie Bai
Format:	Article
Language:	English
Published:	Wiley 2025-07-01
Series:	Cancer Medicine
Subjects:	atrial fibrillation cytokines gene mutation JAK2 V617F myeloproliferative neoplasms
Online Access:	https://doi.org/10.1002/cam4.71015
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

THE JAK2V617F POINT MUTATION INCREASES THE OSTEOCLAST FORMING ABILITY OF MONOCYTES IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS AND MAKES THEIR OSTEOCLASTS MORE SUSCEPTIBLE TO JAK2 INHIBITION
by: Emmanouil Spanoudakis, et al.
Published: (2018-10-01)

Gender and age characteristics of <I>JAK2</I> V617F mutation allelic burden and <I>CALR</I> and <I>MPL</I> driver mutations detection during primary examination of patients with suspected myeloproliferative neoplasms
by: I. A. Olkhovskiy, et al.
Published: (2024-12-01)

Targeting PAR1 activation in JAK2V617F-driven philadelphia-negative myeloproliferative neoplasms: Unraveling its role in thrombosis and disease progression
by: İldeniz USLU-BIÇAK, et al.
Published: (2025-05-01)

Association between JAK2V617F Mutation and Mean Platelet Volume among Myeloproliferative Neoplasm Patients
by: Mushtaq M. Khazeem, et al.
Published: (2025-04-01)

Prevalence and clinicopathological features of driver gene mutations profile in BCR:ABL1 negative classical myeloproliferative neoplasm—A single-center study from North India
by: Khaliqur Rahman, et al.
Published: (2024-12-01)

Relation of JAK2 V617F allele burden and coronary calcium score in patients with essential thrombocythemia
by: Drofenik Ajda, et al.
Published: (2024-10-01)

CHRONIC MYELOPROLIFERATIVE NEOPLASMS: A COLLABORATIVE APPROACH
by: Paola Guglielmelli, et al.
Published: (2010-05-01)

Insights into the role of JAK2-I724T variant in myeloproliferative neoplasms from a unique cohort of New Zealand patients
by: Christopher Puli'uvea, et al.
Published: (2024-12-01)

JAK2V617F-positive clonal hematopoiesis of indeterminate potential in pregnant women
by: I. A. Olkhovskiy, et al.
Published: (2019-09-01)

Exogenous Janus Kinase 617 Codon Influences Small Noncoding RNAs and Gene Expression in Ba/F3 Cells
by: Yi-Yang Chen, et al.
Published: (2024-12-01)

Biology of Myeloproliferative Malignancies
by: AL Melikyan, et al.
Published: (2016-07-01)

Study of Patients with Polycythemia Vera in JAK2V617F and Mutated and Unmutated Status along with their Anxiety and Worried Thoughts: A Single-center Experience from Eastern India
by: Rishu Vidhatri, et al.
Published: (2024-12-01)

A higher JAK2V617F allele burden may be a risk factor for hemorrhagic events in younger patients with polycythemia vera
by: Chiho Furuya, et al.
Published: (2024-12-01)

Activation of integrin signaling up-regulates pro-inflammatory cytokines in JAK2-V617F positive hematopoietic cells
by: Conny K. Baldauf, et al.
Published: (2025-08-01)

Case Report: Myelodysplastic/myeloproliferative neoplasm with concurrent SF3B1, ASXL1, JAK2 and CBL mutations and <15% bone marrow ringed sideroblasts
by: Yifan Wang, et al.
Published: (2025-07-01)

Carotid artery stenting in JAK2 V617F-positive essential thrombocythemia with symptomatic internal carotid artery stenosis: a case report
by: Minghui Du, et al.
Published: (2025-08-01)

HMGB1 as a biomarker for myeloproliferative neoplasm complicated with atherosclerosis
by: Lunbi Wu, et al.
Published: (2025-05-01)

Can Polycythemia Vera evolve from Acute Myeloid Leukemia? A Case Report Showing a Simultaneous Minor JAK2 V617F Mutated Clone,
by: Beatrice Borsellino, et al.
Published: (2022-06-01)

Primary and secondary myelofibrosis: ophthalmological manifestations at onset and during therapy
by: O. Yu. Vinogradova, et al.
Published: (2025-03-01)

Efficacy and safety of pegylated interferon in the treatment of JAK2V617F-positive polycythemia vera with a dose de-escalation strategy: a single-center retrospective study
by: Long Chang, et al.
Published: (2025-05-01)

Myelofibrosis Models: Literature Review and Own Data
by: AA Silyutina, et al.
Published: (2017-01-01)

Correction: Efficacy and safety of pegylated interferon in the treatment of JAK2V617F-positive polycythemia vera with a dose de-escalation strategy: a single-center retrospective study
by: Long Chang, et al.
Published: (2025-06-01)

Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study
by: O. Yu. Vinogradova, et al.
Published: (2024-09-01)

Association of Pruritus With Comorbidities and Survival in Myeloproliferative Neoplasms: A Systematic Review of the Literature
by: J. Saucereau, et al.
Published: (2025-06-01)

Characteristics of regional epidemiological indicators of chronic myeloproliferative neoplasms
by: O. Yu. Vinogradova, et al.
Published: (2025-05-01)

Pro- and Antifibrotic Factors in the Serum of Patients with Chronic Myeloproliferative Disorders
by: AA Silyutina, et al.
Published: (2017-10-01)

CalR and MPL Driver Mutations and Their Role in the Diagnosis and Clinical Course of JAK2-Unmutated Chronic Myeloproliferative Neoplasm: Results from a Pilot Single-Center Study
by: Tarık Onur Tiryaki, et al.
Published: (2025-05-01)

The CHIP-clinic as the catalyst of preventive medicine
by: Hans Carl Hasselbalch, et al.
Published: (2024-10-01)

Unraveling the impact of lysosomal dysfunction on myeloproliferative neoplasm
by: Hyundong Yoon, et al.
Published: (2024-09-01)

Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan
by: Yoko Edahiro, et al.
Published: (2024-12-01)

Genomic profile helps to predict the clonal evolution and outcome of BCR-ABL-negative myeloproliferative neoplasms
by: Xiaodong Guo, et al.
Published: (2025-08-01)

Prevalence and clinical significance of sarcopenia in patients with chronic myeloproliferative neoplasms: epidemiology, diagnosis, and intervention strategies
by: Adelina G. Garifullina, et al.
Published: (2025-01-01)

Identification of Novel Risk Variants of Inflammatory Factors Related to Myeloproliferative Neoplasm: A Bidirectional Mendelian Randomization Study
by: Yang Li, et al.
Published: (2024-01-01)

MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria
by: Mohamed A. Yassin, et al.
Published: (2020-07-01)

Application of heteroduplex analysis for CALR mutation screening detection in patients with Ph-myeloproliferative neoplasms
by: T. N. Subbotina, et al.
Published: (2021-06-01)

CLINICAL AND LABORATORY FEATURES OF ESSENTIAL THROMBOCYTOSIS AND PRIMARY MYELOFIBROSIS DEPENDING ON JAK2 AND CALR1 MUTATION STATUS
by: E. G. lisina, et al.
Published: (2017-10-01)

A Dual-Feature Framework for Enhanced Diagnosis of Myeloproliferative Neoplasm Subtypes Using Artificial Intelligence
by: Amna Bamaqa, et al.
Published: (2025-06-01)

USP5 inhibition via bone marrow-targeted engineered exosomes for myeloproliferative neoplasms therapy
by: Wenjun Wang, et al.
Published: (2025-07-01)

Masked polycythemia vera manifested by splanchnic venous thrombosis during pregnancy: a clinical case
by: M. Yu. Nadinskaia, et al.
Published: (2022-05-01)

Not just for mature audiences: myeloproliferative neoplasms in children, adolescents, and young adults
by: Linda Resar, et al.
Published: (2025-05-01)